Bio Path Holdings Inc (BPTH)

[wordlender]

I expect we get an update on or around the meeting on the 21st. PN already stated that they have 19 or 20 patients enrolled on the last conference call. The full evaluation will take more time and bring us into the first quarter.

The drug has been working. No evidence to suggest, so far, that we have efficacy issues.

This company is tight-lipped. That is not necessarily a bad thing, because other development stage biotechs who were not tight lipped have been accused of pumping the stock artificially or some other wrongdoing.

Our low stock price reflects the limited resources BPTH has and limited progress made over the past 3-5 years. If we can show 40% complete remission rate in the interim analysis, than we should be able to solve both problems. The safety segment had a 50% complete remission rate. The comparison remission rate is 18%, I believe.

Hold on a few more months to see where we end up.